Sirius NeoSight is a technology company.
Sirius NeoSight has raised $5.0M across 1 funding round.
Sirius NeoSight has raised $5.0M in total across 1 funding round.
Sirius NeoSight has raised $5.0M in total across 1 funding round.
Sirius NeoSight's investors include Go Capital, Karista.
Sirius NeoSight is a French biotechnology startup developing a platform to isolate circulating tumor cells (CTCs) by measuring cell membrane fluidity, enabling early detection of cancer recurrences, treatment resistance, and personalized therapy selection.[1][2][4] The technology targets aggressive cancers across multiple types, providing doctors with insights into therapy efficacy and supporting precision oncology by identifying the most effective treatments for individual patients.[1][4] It serves oncologists, hospitals, and cancer research centers, addressing the challenge of detecting subclinical cancers and metastases before clinical symptoms arise, with recent €4.4 million funding fueling platform acceleration.[4]
Sirius NeoSight emerged from a collaboration between biotech entrepreneur Agnès Bastid, with over 15 years in pharma management (including Sanofi Pasteur and Axplora), and scientists Dr. Arnaud Vigneron and Dr. David Gueyrard, originators of the membrane fluidity detection technology.[1] The company was formally created by successful entrepreneurs Jean-Guillaume Lafay and Stéphane Legastelois, building on discoveries from the University of Lyon, CNRS, Hospices Civils de Lyon (HCL), and Léon Bérard Centre (CRCL).[1] Early traction includes close ties with these labs and key oncology stakeholders like Centre Léon Bérard and Institut de Cancérologie de l’Ouest (ICO), culminating in a €4.4 million seed round in 2024 from investors including GO CAPITAL, DEMETER, Evolem, and life sciences angels.[4] Based in Tassin-la-Demi-Lune near Lyon, France, the startup leverages this ecosystem for clinical validation.[1][5]
Sirius NeoSight rides the wave of precision oncology and liquid biopsy advancements, where CTC analysis addresses limitations in imaging and tissue biopsies for real-time metastasis and resistance tracking.[1][2] Timing aligns with surging demand for non-invasive, early-detection tools amid rising cancer incidence and immunotherapy adoption, amplified by EU and French biotech incentives like Bpifrance grants.[4] Market forces favoring it include aging populations, aggressive cancer prevalence, and a shift to personalized treatments, with its universal applicability filling gaps in type-specific diagnostics.[1] By influencing ecosystems through collaborations with centers like Léon Bérard and ICO, it accelerates clinical translation, potentially shaping standards in oncology biotech.[1][4]
Sirius NeoSight is poised for clinical trials and regulatory milestones, leveraging its €4.4 million raise to refine the platform for market entry, targeting broader CTC-based assays by 2026-2027.[4] Trends like AI-enhanced diagnostics and multi-omics integration will amplify its membrane fluidity tech, while expanding partnerships could drive global adoption amid oncology's projected $100B+ liquid biopsy market. Its influence may evolve from niche innovator to key player in personalized cancer care, delivering the "new view" promised—transforming early detection into actionable therapy, much like its founding vision to outpace cancer's spread.[1]
Sirius NeoSight has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in February 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2025 | $5.0M Seed | Go Capital, Karista |